Unos científicos han descrito por vez primera cómo una especie de “remache molecular” le permite a la bacteria Pseudomonas aeruginosa reforzar su envoltura y resistir el ataque de los antibióticos. La Pseudomonas aeruginosa es una de las quince bacterias farmacorresi …
Hallan el punto débil de una de las bacterias más resistentes a los antibióticos Read More »
Se ha comprobado en un estudio reciente que introducir una cantidad controlada de caos puede mejorar el aprendizaje de las redes neuronales artificiales, sistemas computacionales clave para la inteligencia artificial que se inspiran en las neuronas biológicas. El estudio es obra de P …
Una dosis de caos para fortalecer la inteligencia artificial Read More »
The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in a suit filed Friday.
CVS sues to challenge new Tennessee PBM-pharmacy breakup law Read More »
The health system received UNC’s offer to combine days after publicly announcing plans to merge with Charlotte, North Carolina-based Atrium Health. Ultimately, WakeMed decided Atrium is the best path forward.
WakeMed declined merger proposal from UNC Health in midst of Atrium deal Read More »
The acquisition is the latest in a series of agreements between DePuy Synthes and organizations associated with entrepreneur Stéphane Lavallée.
J&J’s DePuy Synthes inks deal to buy orthopedic surgery tech Read More »
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Read More »
The recall is Insulet’s second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported.
FDA veteran Peter Marks will now shape the future of Eli Lilly’s vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
Lilly just bought renowned regulator Peter Marks a pipeline to play with Read More »
Nearly 80% of patients saw tumor shrinkage after being treated with Kura Oncology’s darlifarnib plus Bristol Myers Squibb’s Krazati, findings Mizuho analysts say could open up a $2 billion opportunity for the biotech.
Kura’s encouraging cancer drug data could unlock $2B market opportunity Read More »
The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.
FDA assembles vaccine experts to update COVID-19 formulation Read More »
